Stone House Investment Management’s NewAmsterdam Pharma NAMS Stock Holding History

Stone House Investment Management’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11K	Hold	325	–	–	﹤0.01%	419
2026 Q1	$10.4K	Hold	325	–	–	﹤0.01%	345
2025 Q4	$11.4K	Hold	325	–	–	﹤0.01%	307
2025 Q3	$9.24K	Hold	325	–	–	﹤0.01%	298
2025 Q2	$5.89K	Hold	325	–	–	﹤0.01%	304
2025 Q1	$6.65K	Buy	+325	New	+$7.22K	﹤0.01%	287
2024 Q4	–	Sell	-325	Closed	-$5.39K	–	246
2024 Q3	$5.39K	Hold	325	–	–	﹤0.01%	267
2024 Q2	$6.24K	Hold	325	–	–	﹤0.01%	260
2024 Q1	$7.69K	Buy	+325	New	+$6.6K	﹤0.01%	251

Other funds holding NAMS

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Stone House Investment Management's NAMS Position: Q2 2026 in Review

Stone House Investment Management held its NewAmsterdam Pharma (NAMS) position steady in Q2 2026 at 325 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #419.

Stone House Investment Management first reported a position in NAMS in Q1 2024 and has held it in 9 quarters since. The position peaked at $11.4K in Q4 2025. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Stone House Investment Management held 325 shares of NewAmsterdam Pharma worth $11K as of Q2 2026.
Stone House Investment Management left its NewAmsterdam Pharma share count unchanged in Q2 2026.
NewAmsterdam Pharma made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #419 holding.
Stone House Investment Management first reported a position in NewAmsterdam Pharma in Q1 2024 and has held it in 9 quarters since.
Stone House Investment Management's NewAmsterdam Pharma position peaked at $11.4K in Q4 2025.
194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.